UPA Tesamorelin (GHRH) 2mg

UPA Tesamorelin 2mg is a self-mix peptide product containing Tesamorelin, a synthetic analogue of Growth Hormone-Releasing Hormone (GHRH). Each package contains a stated 2mg Tesamorelin vial, accompanied by 2ml of bacteriostatic water.

Tesamorelin stimulates the body's natural release of growth hormone (GH), which subsequently influences insulin-like growth factor 1 (IGF-1) production and metabolic activity.

What UPA Tesamorelin Is Used For

Tesamorelin is associated with growth hormone stimulation and metabolic regulation.

• Visceral Fat Reduction: Approved pharmaceutical Tesamorelin is used to reduce excess abdominal visceral fat in adults with HIV-associated lipodystrophy.

• Growth Hormone Stimulation: Encourages the pituitary gland to release endogenous growth hormone.

• IGF-1 Production: Increases IGF-1 levels through growth hormone-related signalling.

• Fat Metabolism: Influences biological pathways involved in lipid metabolism.

• Body Composition Research: Investigated for its effects on visceral adipose tissue and metabolic health.

• Protein Metabolism: Growth hormone activity influences tissue maintenance and protein metabolism.

How UPA Tesamorelin Works

Tesamorelin acts as a Growth Hormone-Releasing Hormone (GHRH) receptor agonist, stimulating the body's natural growth hormone secretion.

• GHRH Receptor Activation: Binds to receptors in the anterior pituitary gland.

• Growth Hormone Release: Stimulates the secretion of endogenous growth hormone.

• IGF-1 Stimulation: Increased growth hormone activity encourages IGF-1 production.

• Fat Metabolism: Growth hormone influences lipolysis and fat utilisation.

• Visceral Fat Regulation: Clinical studies of approved Tesamorelin formulations have demonstrated reductions in abdominal visceral adipose tissue in specific patient populations.

• Metabolic Signalling: Influences biological pathways involved in glucose and lipid metabolism.

Unlike injectable Somatropin, Tesamorelin does not directly supply growth hormone. Instead, it stimulates the pituitary gland to release the body's existing growth hormone.

Possible Side Effects

Tesamorelin may cause adverse effects associated with increased growth hormone and IGF-1 activity.

Common or Recognised Side Effects:

• Injection-site redness, swelling or irritation.

• Joint pain and stiffness.

• Muscle discomfort.

• Water retention and swelling.

• Headaches.

• Tingling or numbness in the hands.

• Carpal tunnel syndrome.

• Nausea or gastrointestinal discomfort.

• Increased blood glucose levels.

• Reduced insulin sensitivity.

• Allergic or hypersensitivity reactions.